# US 2013/0260389 A1 · Beta-2 microglobulin as a biomarker for peripheral artery disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0260389 A1
- Document ID: US20130260389A1
- Status: Published application
- Kind: A1
- Application number: 13/743,114
- Filed: 2013-01-16
- Published: 2013-10-03
- Earliest claimed: 2006-03-11
- Assignees: Board of Trustees of the Leland Stanford Junior Un University; Vermillion, Inc.
- Applicants: Vermillion, Inc.; Board of Trustees of the Leland Stanford Junior University
- Inventors: John P. Cooke; Eric T. Fung; Eiichiro Kimura
- Web page: https://patentgrep.com/patent/US20130260389A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/323: Arteriosclerosis, Stenosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

A method for qualifying peripheral artery disease status in a subject comprising:
(a) measuring lysozyme in a biological sample from the subject; and
(b) correlating the measurement or measurements with peripheral artery disease versus non-peripheral artery disease.

### Claim 29 (depends on 28)

The method of claim 28, further comprising measuring β2-microglobulin.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 28)

The method of claim 28, wherein said measurement or measurements of a biomarker is performed using mass spectrometry or an immunoassay.

### Claim 33 (depends on 28)

The method of claim 28, further comprising measuring cystatin C or β2-microglobulin.

### Claim 34 (depends on 32)

The method of claim 32, wherein mass spectrometry is SELDI-MS.

### Claim 35 (depends on 28)

The method of claim 28, wherein the sample is blood, serum, or plasma.

### Claim 36 (depends on 28)

The method of claim 28, wherein the correlating is performed by executing a software classification algorithm.

### Claim 37 (depends on 28)

The method of claim 28, further comprising: (c) reporting the status to the subject.

### Claim 38 (depends on 28)

The method of claim 28, further comprising: (c) recording the status on a tangible medium.

### Claim 39 (depends on 28)

The method of claim 28, further comprising: (c) managing subject treatment based on the status.

### Claim 40 (depends on 28)

The method of claim 28, further comprising: (d) measuring the at least one biomarker after subject management and correlating the measurement with disease progression.
